29 results
SC TO-T
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Third party tender offer statement
5:24pm
irreparable injury to Discloser, entitling Discloser to seek injunctive relief in addition to all legal remedies.
MISCELLANEOUS
This Agreement will bind
8-K
EX-10.2
k43kat1r6n1q9500q1r
7 Jun 21
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
8:07am
10-Q
65qfp 5me5
17 May 21
Quarterly report
4:26pm
DEF 14A
zp42j4q
30 Apr 21
Definitive proxy
9:13am
10-K
6esvkr7naqpm
29 Mar 21
Annual report
4:26pm
424B4
iwbx74q7 h448gq
3 Dec 20
Prospectus supplement with pricing info
4:48pm
S-1/A
nl9k1k2dmz2yl 4mir
30 Nov 20
IPO registration (amended)
6:05am
S-1
EX-10.12
b43bupskpdp
13 Nov 20
IPO registration
5:03pm